Stephens Inc. AR Boosts Stake in Danaher Corporation $DHR

Stephens Inc. AR raised its holdings in shares of Danaher Corporation (NYSE:DHR) by 1.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,349 shares of the conglomerate’s stock after buying an additional 144 shares during the quarter. Stephens Inc. AR’s holdings in Danaher were worth $2,242,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of DHR. GHP Investment Advisors Inc. boosted its holdings in shares of Danaher by 396.0% in the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate’s stock worth $25,000 after purchasing an additional 99 shares in the last quarter. Sierra Ocean LLC raised its position in Danaher by 116.9% during the 1st quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate’s stock valued at $29,000 after purchasing an additional 76 shares during the last quarter. Red Tortoise LLC raised its position in Danaher by 175.0% during the 2nd quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock valued at $30,000 after purchasing an additional 98 shares during the last quarter. Smallwood Wealth Investment Management LLC bought a new position in Danaher during the 1st quarter valued at approximately $31,000. Finally, Ramirez Asset Management Inc. bought a new position in shares of Danaher in the 2nd quarter worth approximately $40,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Price Performance

NYSE:DHR opened at $218.06 on Thursday. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $156.14 billion, a P/E ratio of 44.96, a P/E/G ratio of 3.20 and a beta of 0.77. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $260.88. The business’s 50-day moving average is $202.24 and its 200 day moving average is $197.73.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, October 21st. The conglomerate reported $1.89 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. The company had revenue of $6.05 billion for the quarter, compared to the consensus estimate of $6 billion. Danaher had a return on equity of 10.93% and a net margin of 14.44%.The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same period in the previous year, the business earned $1.71 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, equities research analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, September 26th. Danaher’s payout ratio is presently 27.23%.

Insiders Place Their Bets

In other Danaher news, Director Teri List sold 2,778 shares of the business’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the sale, the director directly owned 20,751 shares of the company’s stock, valued at $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 11.10% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

DHR has been the subject of several research reports. UBS Group decreased their target price on Danaher from $240.00 to $225.00 and set a “buy” rating for the company in a research report on Wednesday, July 23rd. Rothschild Redb downgraded Danaher from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 8th. Royal Bank Of Canada set a $241.00 price objective on Danaher in a report on Tuesday, September 2nd. Rothschild & Co Redburn reaffirmed a “neutral” rating and issued a $220.00 price objective (down previously from $245.00) on shares of Danaher in a report on Wednesday, October 8th. Finally, Deutsche Bank Aktiengesellschaft lifted their target price on Danaher from $235.00 to $250.00 and gave the company a “buy” rating in a research report on Wednesday. Seventeen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, Danaher has an average rating of “Moderate Buy” and a consensus target price of $243.39.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.